Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial

• Published in: BMC infectious diseases Vol. 20; no. 1; pp. 954 - 10
• Main Authors: Nojomi, Marzieh, Yassin, Zeynab, Keyvani, Hossein, Makiani, Mahin Jamshidi, Roham, Maryam, Laali, Azadeh, Dehghan, Nasir, Navaei, Mehrnaz, Ranjbar, Mitra
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14.12.2020; BioMed Central; BMC
• Subjects: Adult; Aged; Antiretroviral drugs; Antiviral agents; Antiviral Agents - therapeutic use; Antiviral drugs; Arbidol; Blood; Cardiovascular disease; Clinical trials; Corona virus; Coronaviruses; Cough; COVID-19; COVID-19 Drug Treatment; Disease transmission; Drug Combinations; Dyspnea; Efficacy; FDA approval; Female; Fever; Hospitalization; Humans; Hydroxychloroquine; Hydroxychloroquine - therapeutic use; Immunomodulators; Independent variables; Indoles - therapeutic use; Lopinavir; Lopinavir - therapeutic use; Male; Medical imaging; Middle Aged; Neutrophils; Oxygen; Oxygen content; Pandemics; Patients; Pharmacology, Experimental; Public health; Regression analysis; Respiration; Ritonavir; Ritonavir - therapeutic use; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Signs and symptoms; Teaching hospitals; Variance analysis; Viruses; Iran; China; COVID-19; Corona virus; Efficacy; Arbidol

Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine th...